Candel Therapeutics Unveils CAN-3110 Melanoma Data at SITC 2024
NEEDHAM, Mass. — Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a dynamic biopharmaceutical entity focused on pioneering multimodal biological immunotherapies, is excited to share insights about its upcoming presentation at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting. This significant event is set to take place in early November and will highlight innovations in cancer treatment, specifically targeting melanoma.
Presentation Overview
The presentation is poised to be a landmark moment for Candel as the Company unveils a poster detailing the therapeutic potential of its innovative therapy, CAN-3110, in patients with melanoma characterized by alterations in the Ras-Raf pathway. The specifics of the presentation are set forth as follows:
Title: Therapeutic potential of CAN-3110 in Ras-Raf pathway altered melanoma
Presenter: Anne Diers, PhD, Senior Director, Research, Candel Therapeutics
Abstract Number: 995
Session Date: November 8, 2024
Location: Exhibit Halls A and B – George R. Brown Convention Center
Insights on CAN-3110
At the heart of this presentation is CAN-3110, a groundbreaking, first-in-class oncolytic viral immunotherapy derived from the herpes simplex virus-1 (HSV-1). This therapy is uniquely designed for both oncolysis and immune activation, making it a dual-action treatment. Its functionality hinges on the specific expression of the Nestin protein within cancer cells, allowing for targeted therapeutic strategies.
Currently, CAN-3110 is undergoing a phase 1b clinical trial focused on patients with recurrent high-grade glioma (rHGG). The initial findings from this trial have been promising. In a study published in a renowned scientific journal, the treatment was well tolerated, and no dose-limiting toxicities were observed. Moreover, a notable enhancement in median overall survival has been documented when compared to historical controls, showcasing CAN-3110’s potential in challenging therapeutic conditions.
Expanding Clinical Reach
As part of ongoing research efforts supported by the Break Through Cancer Foundation, Candel is collaborating with academic partners to further evaluate the impact of administering multiple CAN-3110 doses in rHGG. Encouragingly, this candidate has already garnered FDA Fast Track and Orphan Drug Designations, underlining its considerable potential in addressing urgent unmet medical needs.
About Candel Therapeutics
Candel Therapeutics stands at the forefront of biopharmaceutical innovation, dedicated to developing ready-to-use multimodal biological immunotherapies aimed at eliciting personalized, systemic anti-tumor immune responses. The company's strategic focus has led to the creation of two distinctive clinical-stage platforms rooted in genetically modified adenoviruses and HSV gene constructs.
Among its portfolio, CAN-2409 leads the adenovirus platform, which currently is being tested through various clinical trials targeting non-small cell lung cancer, borderline resectable pancreatic cancer, and localized prostate cancer. As the flagship offering from the HSV platform, CAN-3110 continues to pave the way for advancements in the treatment of rHGG.
In addition to these innovations, Candel’s unique enLIGHTEN™ Discovery Platform utilizes advanced analytics and human biology to systematically develop new viral immunotherapies tailored for solid tumors, further reinforcing the Company’s commitment to cancer treatment advancements.
Frequently Asked Questions
What will Candel Therapeutics present at SITC 2024?
Candel will present a poster highlighting the therapeutic potential of CAN-3110 in melanoma, particularly in cases with Ras-Raf pathway alterations.
What is CAN-3110?
CAN-3110 is an oncolytic viral immunotherapy designed from HSV-1, which aims to activate the immune system while targeting cancer cells that express Nestin.
In which trial is CAN-3110 currently involved?
CAN-3110 is participating in a phase 1b clinical trial focusing on patients with recurrent high-grade glioma.
What are the early results from the CAN-3110 clinical trial?
Initial results indicate that CAN-3110 is well tolerated with no dose-limiting toxicities, and it has shown improved survival rates compared to historical data.
How does Candel Therapeutics contribute to cancer research?
Candel Therapeutics develops innovative biopharmaceutical therapies designed to evoke personalized immune responses against various types of cancer, enhancing treatment options for patients.
